Recombinant alpha-fetoprotein heterogenen L3 antigen and its preparation method and application
By constructing recombinant alpha-fetoprotein (AFP) isoform L3 chimeric antigen on a human serum albumin scaffold, the problems of disulfide bond mismatch and low glycosylation efficiency in existing technologies have been solved, achieving efficient and stable detection of AFP isoform L3, reducing costs and improving batch-to-batch consistency and long-term stability.
Patent Information
- Application Number
- CN202610735445.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-26
- Publication Date
- 2026-07-17
AI Technical Summary
Existing recombinant alpha-fetoprotein isoform L3 antigen has problems such as disulfide bond mismatch, low glycosylation efficiency, and conformational masking leading to insufficient titer in detection. Furthermore, the calibrators are difficult to prepare, have large batch-to-batch variability, poor stability, and high cost.
The glycosylation island sequence of alpha-fetoprotein isoform L3 was precisely transplanted onto a stable scaffold of human serum albumin to construct a recombinant alpha-fetoprotein isoform L3 chimeric antigen. The stable monomeric structure of human serum albumin was used to avoid dimer/oligomer tendencies, and mismatched disulfide bonds were eliminated through site-directed mutagenesis to ensure that the glycosylation sites can be recognized by antibodies in a non-denatured, non-reducing state.
It achieves a significant increase in antibody binding efficiency, a 10-fold increase in yield, excellent purity and stability, good batch-to-batch consistency, reduced costs, and detection results that are highly consistent with natural antigens without the need for reducing agent pretreatment. It also demonstrates superior long-term storage stability compared to natural antigens.
Smart Images
Figure CN122404525A_ABST